Co-Diagnostics, Inc. Awarded $1.2M Funding For Co-Dx PCR Home Platform From NIH RADx Tech Program
Portfolio Pulse from Happy Mohamed
Co-Diagnostics, Inc. (NASDAQ:CODX) has been awarded $1.2 million in funding from the National Institutes of Health (NIH) as part of the Rapid Acceleration of Diagnostics (RADx®) Tech program. The funds will be used to complete the development of its flu A/B, COVID-19, and RSV multiplex test on the Co-Dx PCR Home™ testing platform, which is currently undergoing clinical evaluations in anticipation of its submission to the FDA.
July 13, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Co-Diagnostics, Inc. has received a $1.2 million grant from the NIH. This funding will be used to complete the development of its multiplex test on the Co-Dx PCR Home™ platform, which is currently undergoing clinical evaluations.
The funding from NIH will help Co-Diagnostics, Inc. to complete the development of its multiplex test, which could potentially increase the company's revenues once the product is launched. This news is highly relevant and important for the company and its investors, hence the high scores.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100